TP53 and acute myeloid leukemia: Centrinone treatment leads to a decrease in colony forming ability and induces apoptosis and G2/M arrest in acute myeloid leukemia (AML) cells [50, 51]. CFI-400945 (and centrinone B) show antitumorigenic effects in p53-mutated AML cells, such as suppression of cell growth, induction of DNA damage responses, apoptosis, senescence and polyploidy, activation of the immune response and remodeling of histone methylation [77]. CFI-400945 treatment leads to antitumor effects in leukemia cell lines and AML xenograft models [78].